These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20361941)

  • 21. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance.
    Cimbora-Zovko T; Ambriović-Ristov A; Loncarek J; Osmak M
    Eur J Pharmacol; 2007 Mar; 558(1-3):27-36. PubMed ID: 17234182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
    Wang G; Dombkowski A; Chuang L; Xu XX
    Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation.
    Kasuga C; Nakahara Y; Ueda S; Hawkins C; Taylor MD; Smith CA; Rutka JT
    J Neurosurg Pediatr; 2008 Apr; 1(4):305-13. PubMed ID: 18377306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines.
    Tanabe M; Izumi H; Ise T; Higuchi S; Yamori T; Yasumoto K; Kohno K
    Cancer Res; 2003 Dec; 63(24):8592-5. PubMed ID: 14695168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
    Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
    Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
    Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
    Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells.
    Hirano G; Izumi H; Kidani A; Yasuniwa Y; Han B; Kusaba H; Akashi K; Kuwano M; Kohno K
    Mol Cancer Res; 2010 Jun; 8(6):864-72. PubMed ID: 20530585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nox4 inhibition enhances the cytotoxicity of cisplatin in human renal cancer cells.
    Chang G; Chen L; Lin HM; Lin Y; Maranchie JK
    J Exp Ther Oncol; 2012; 10(1):9-18. PubMed ID: 22946340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knockdown of NAPA using short-hairpin RNA sensitizes cancer cells to cisplatin: implications to overcome chemoresistance.
    Wu ZZ; Chao CC
    Biochem Pharmacol; 2010 Sep; 80(6):827-37. PubMed ID: 20653109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O; Arce F; Gätjens-Boniche O; Díaz C
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
    Gaddameedhi S; Chatterjee S
    J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
    Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
    Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in the glycoform of cisplatin-resistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system.
    Nakagawa H; Ohira M; Hayashi S; Abe S; Saito S; Nagahori N; Monde K; Shinohara Y; Fujitani N; Kondo H; Akiyama S; Nakagawara A; Nishimura S
    Cancer Lett; 2008 Nov; 270(2):295-301. PubMed ID: 18573595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
    Asada N; Tsuchiya H; Tomita K
    Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
    Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
    Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
    Reinhold WC; Kouros-Mehr H; Kohn KW; Maunakea AK; Lababidi S; Roschke A; Stover K; Alexander J; Pantazis P; Miller L; Liu E; Kirsch IR; Urasaki Y; Pommier Y; Weinstein JN
    Cancer Res; 2003 Mar; 63(5):1000-11. PubMed ID: 12615715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
    Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
    Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.